Study aim: Determining the effect of herbal tea (including mallow flower, chicory seeds, sweet violet flower, Melilotus officinalis and Bindii) on improving respiratory symptoms in patients with Covid-19 Design: A clinical trial, with the parallel groups, no blinding, randomized Settings and conduct: This not blind, randomized clinical trial will be performed at shafa hospital. This study will be performed on 40 patients with Covid-19 in two groups. One group is treated with hydroxychloroquine. The other group will receive herbal tea in addition to hydroxychloroquine treatment. Participants/Inclusion and exclusion criteria: Inclusion criteria: Positive result of PCR or CT scan for COVID-19 disease in accordance with international standards Age 60-15 years Patient consent to participate in the study exclusion criteria: Has diseases such as Alzheimer's, Parkinson's, multiple sclerosis, neuromuscular diseases, myasthenia gravis Pregnant women Patients with blood pressure lower than 40/90 mmHg Breathe more or equal to 30 per minute Blood oxygen saturation less than 93% at rest PaO2 to FiO2 ratio less than or equal to 300 mmHg Patients with more than 50% of exudative lesions in 24-48 hours in the lung image Intervention groups: Control group: Patients in this group will receive only the routine treatment. Intervention group: Patients in this group, in addition to receiving routine treatment, will use the herbal tea including mallow flower, chicory seeds, sweet violet flower, Melilotus officinalis and Bindii. In this way, a jam spoon (equivalent to 5 grams of powdered this herbal composition) with a cup of boiling water (equivalent to 150 cc) is brewed for 25-30 minutes and after straining it is given to the patient. This herbal tea will be prescribed half an hour after lunch for 5 days. Main outcome variables: Early signs; Clinical manifestations; Patient outcome